{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-004881","form_type":"8-K","ticker":"KTTA","cik":"0001841330","company_name":"Pasithea Therapeutics Corp.","filed_at":"2023-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.049981+00:00","generated_at":"2026-06-20T10:59:48.501570+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pasithea Therapeutics receives Nasdaq deficiency notice for minimum bid price non-compliance","bullets":["Received Nasdaq notice on Jan 19, 2023 for failure to meet $1.00 minimum bid price rule (Nasdaq 5550(a)(2)).","Company has 180 calendar days, until July 18, 2023, to regain compliance; stock must close at $1.00+ for 10 consecutive days.","If not cured, may request additional 180 days if meeting other listing requirements and intending reverse stock split.","Failure to regain compliance could lead to delisting; company is considering options to cure deficiency.","Receipt of notice does not affect business operations or SEC reporting requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-004881","json":"https://secwatch.observer/filing/0001213900-23-004881.json","markdown":"https://secwatch.observer/filing/0001213900-23-004881.md","text":"https://secwatch.observer/filing/0001213900-23-004881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841330/000121390023004881/0001213900-23-004881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841330/000121390023004881/ea172094-8k_pasithea.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T10:59:48.501570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea8e07669fdaeb9e431cdd5c3441080c8a6e455f","claim":"Pasithea Therapeutics Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"January 19, 2023, Pasithea Therapeutics Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid pri","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390023004881/0001213900-23-004881-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}